Prescribing patterns for treating common complications of spinal cord injury
- PMID: 33955832
- PMCID: PMC9987774
- DOI: 10.1080/10790268.2021.1920786
Prescribing patterns for treating common complications of spinal cord injury
Abstract
Objective: The purpose of this study was to find the most and least commonly prescribed medications for treating secondary health complications associated with spinal cord injury (SCI); and determine overall polypharmacy rates and risk factors associated with it.
Design: Observational design, cross-sectional analysis.
Setting: Community; Canada.
Participants: Individuals with spinal cord injury (n = 108).
Results: A total of 515 prescriptions were issued to the sample comprising 213 different medications to treat 10 SCI-related complications. Forty-five (45%) participants were prescribed >5 medications concurrently. No associations were found between the number of drugs taken and age, sex, level of injury, completeness of injury, time since injury, or cause of injury. The most commonly treated complications included pain (56.5%), muscle spasms (54%) and urinary tract infections (43%). Anti-convulsants (pregabalin, gabapentin), anti-spasmodics (baclofen, diazepam) and nitrofurantoins (Macrobid) were the most commonly prescribed medications to treat each of the three conditions, respectively. Thirty five percent of the total sample received a combination of two or more analgesics including fourth-line agents in the opiate class (hydromorphone, hydrocodone and morphine). Similarly, some participants were prescribed general muscle relaxants and cephalosporins for treatment of muscle spasms and urinary tract infections, respectively, that are generally not recommended in SCI patients. We compare these prescribing patterns with the available clinical practice guidelines and highlight areas where the prescriptions fall outside the recommended clinical practice while considering the complexity of medication management in SCI.
Conclusion: Medication management in SCI is complex. Tools are required that enable prescribers to choose evidence-based medical regimens and deprescribe potentially inappropriate medications for their patients with SCI.
Keywords: Medication management; Polypharmacy; Prescription patterns; Secondary health conditions; Spinal cord injury.
Similar articles
-
Prescribing for common complications of spinal cord injury.Can Fam Physician. 2022 Dec;68(12):885-888. doi: 10.46747/cfp.6812885. Can Fam Physician. 2022. PMID: 36515049 Free PMC article.
-
Potentially harmful drug-drug interactions in the therapeutic regimens of persons with spinal cord injury.J Spinal Cord Med. 2024 Sep;47(5):692-700. doi: 10.1080/10790268.2023.2185399. Epub 2023 Mar 27. J Spinal Cord Med. 2024. PMID: 36972222 Free PMC article.
-
The risks of polypharmacy following spinal cord injury.J Spinal Cord Med. 2017 Mar;40(2):147-153. doi: 10.1179/2045772314Y.0000000235. Epub 2016 Mar 9. J Spinal Cord Med. 2017. PMID: 24970339 Free PMC article.
-
Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis.Arch Phys Med Rehabil. 2014 Nov;95(11):2180-6. doi: 10.1016/j.apmr.2014.06.010. Epub 2014 Jun 30. Arch Phys Med Rehabil. 2014. PMID: 24992021 Review.
-
Spinal cord injury and polypharmacy: a scoping review.Disabil Rehabil. 2020 Dec;42(26):3858-3870. doi: 10.1080/09638288.2019.1610085. Epub 2019 May 9. Disabil Rehabil. 2020. PMID: 31068029
Cited by
-
Prescribing for common complications of spinal cord injury.Can Fam Physician. 2022 Dec;68(12):885-888. doi: 10.46747/cfp.6812885. Can Fam Physician. 2022. PMID: 36515049 Free PMC article.
-
Self-reported benzodiazepine use among adults with chronic spinal cord injury in the southeastern USA: associations with demographic, injury, and opioid use characteristics.Spinal Cord. 2024 Nov;62(11):667-673. doi: 10.1038/s41393-024-01030-4. Epub 2024 Sep 13. Spinal Cord. 2024. PMID: 39271797 Free PMC article.
-
Potentially harmful drug-drug interactions in the therapeutic regimens of persons with spinal cord injury.J Spinal Cord Med. 2024 Sep;47(5):692-700. doi: 10.1080/10790268.2023.2185399. Epub 2023 Mar 27. J Spinal Cord Med. 2024. PMID: 36972222 Free PMC article.
-
The Effect of Antinociceptive Dose of Morphine on Cell Therapy in Rats with Spinal Cord Injury.Mol Neurobiol. 2025 Feb;62(2):1620-1630. doi: 10.1007/s12035-024-04350-x. Epub 2024 Jul 16. Mol Neurobiol. 2025. PMID: 39012442
-
Role of gabapentin in the management of neurogenic overactive bladders: A systematic review.Cent European J Urol. 2025;78(1):61-69. doi: 10.5173/ceju.2024.0125. Epub 2025 Mar 21. Cent European J Urol. 2025. PMID: 40371430 Free PMC article. Review.
References
-
- Rabchevsky AG, Patel SP, Springer JE.. Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward? Pharmacol Therap (Oxford) 2011;132(1):15–29. - PubMed
-
- Jensen EK, Biering-Sørensen F.. Medication before and after a spinal cord lesion. Spinal Cord 2014;52(5):358–63. - PubMed
-
- Rouleau P, Guertin PA.. Traumatic and nontraumatic spinal-cord-injured patients in Quebec, Canada. Part 3: pharmacological characteristics. Spinal Cord 2011;49(2):186–95. - PubMed
-
- Dryden DM, Saunders LD, Rowe BH, May LA, Yiannakoulias N, Svenson LW, et al. . Utilization of health services following spinal cord injury: a 6-year follow-up study. Spinal Cord 2004;42(9):513–25. - PubMed
-
- Hitzig SL, Tonack M, Campbell KA, McGillivray CF, Boschen KA, Richards K, et al. . Secondary health complications in an aging Canadian spinal cord injury sample. Am J Phys Med Rehabil 2008;87(July):545–55. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical